Clinical Trial

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

Study acronym: ELIMINATE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study from time of enrollment is 18-20 months.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2024-02-20; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2024-08-27
Trial Details
NCT Number NCT06280950
Lead Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Liver Transplant
Enrollment 340 participants
Start Date 2024-09-12
Primary Completion 2028-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-24